OncoSec: Rises as dosing begins in COVID-19 vaccine candidate study

OncoSec Medical Incorporated

27/01/2021 19:13

** Immunotherapy developer's shares  ONCS.O  rise 3.9% to
$7.09
    ** Co says it has dosed several participants in early-stage
trial testing its COVID-19 vaccine candidate, CORVax12
 urn:newsml:reuters.com:*:nPnK43lPa
    ** Study will evaluate safety and immunogenicity of the
vaccine candidate in up to 36 healthy volunteers; CORVax12 will
be given as a prime dose and a booster dose four weeks apart -
ONCS
    ** Co believes CORVax12 may also be able to protect those at
higher risk for complications from the coronavirus, including
cancer, transplant and elderly patients
    ** Stock up 8.5% YTD

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))